Quality validation of data in national haemovigilance systems in Europe: report of a survey on current state of practice.
European Union member states must have national haemovigilance reporting of serious adverse reactions and events. We sent national competent authorities an email questionnaire about data validation. Responses were received from 23/27 countries. Nine previously had no national haemovigilance system. In 13 (57%), the serious adverse reactions and events can be verified. Coverage of blood establishments is documented in 20 systems (87%) and of hospitals in 15 systems (65%). Although all member states have implemented haemovigilance systems, there are currently wide variations in data quality assurance, not allowing comparisons between countries.
TRIP (Transfusion Reactions in Patients) Dutch National Hemovigilance Office, The Hague, The Netherlands. j.wiersum@tripnet.nl
J C
JC
Wiersum-Osselton
J C
JC
Faber
C
C
Politis
A
A
Brand
J G
JG
van der Bom
M R
MR
Schipperus
D001771:Blood Banks / Q000592:standards*; D058731:Blood Safety / Q000592:standards*; D001803:Blood Transfusion / Q000592:standards*; D003625:Data Collection / Q000379:methods; D005062:European Union; D006801:Humans; D038622:Internationality; D011785:Quality Assurance, Health Care; D015203:Reproducibility of Results; D011795:Surveys and Questionnaires; D065227:Transfusion Reaction